FDA classifies orthopedic wearable that vibrates its way into regulation
Published Date: 11/5/2026
Rule
Summary
The FDA has officially placed wearable vibration devices for orthopedic use into Class II, meaning they now have special safety rules but face fewer regulatory hurdles. This change helps patients get access to these innovative devices faster while keeping safety in check. The new classification took effect on November 5, 2026, but has been in place since January 12, 2024, making it easier and potentially cheaper for makers to bring these devices to market.
Analyzed Economic Effects
4 provisions identified: 3 benefits, 1 costs, 0 mixed.
Wearable orthopedic vibration devices reclassified
The FDA has classified wearable vibration devices for orthopedic use as Class II (special controls). This order is effective November 5, 2026, and the classification has been applicable since January 12, 2024; FDA says the change reduces regulatory burdens and will enhance patients' access to these devices.
De Novo creates predicate for future devices
Because FDA granted De Novo classification for this device type, the wearable vibration device can serve as a predicate for future devices. That means other device sponsors can use the less-burdensome 510(k) pathway rather than a premarket approval application when marketing substantially equivalent devices.
Device remains subject to 510(k) premarket notification
The FDA states that wearable vibration devices for orthopedic use are subject to premarket notification under section 510(k) of the FD&C Act, and FDA has not determined that this device type should be exempt under section 510(m). Manufacturers must therefore submit a 510(k) unless and until an exemption is granted.
New special controls require safety and labeling tests
The final order establishes special controls that require clinical performance testing (including at least 1 year of follow-up), non-clinical performance testing (device output characterization and validation that vibration is within safe physiologic limits), biocompatibility, electrical/mechanical/thermal/battery/electromagnetic safety testing, software verification and validation, human factors/usability evaluation, and specific labeling (including a summary of clinical performance and observed adverse events, instructions on duration/frequency and when to stop, and maintenance/cleaning/disposal instructions).
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-22584, Approval and Promulgation of State Plans for Designated Facilities and Pollutants; West Virginia; Control of Emissions From Existing Municipal Solid Waste Landfills
Next: 2026-22590, Medical Devices; Neurological Devices; Classification of the Prognostic Assessment Software of Mild Cognitive Impairment
The FDA is officially putting mild cognitive impairment prognostic software into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to these helpful tools faster and ensures the devices are safe and effective. The new rules took effect November 5, 2026, but have been in place since January 11, 2024, giving companies clear guidance on what’s expected.